ヒトにおける慢性的なムオピオイド受容体刺激は,筋肉の交感神経の活動を低下させる
P Kienbaum1, T Heuter, M C Michel
1Abteilung für Anästhesiologie und Intensivmedizin, Biochemisches Forschungslabor, and Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Essen, Germany. peter.kienbaum@uni-essen.de
Circulation
|February 15, 2001
まとめ
オピオイド中毒患者の慢性的なメタドン使用は,筋肉の交感神経活動 (MSA) を著しく低下させます. 交感性神経系活動におけるこの減少は,ミュオピオイド受容体阻害によって逆転する.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 心血管生理学 心血管の生理学
背景:
- オピオイド依存症の治療には,解毒が含まれ,慢性的なオピオイド効果の洞察を提供します.
- 慢性的なオピオイド受容体刺激に対する交感神経系の反応は完全に理解されていません.
研究 の 目的:
- 慢性的な経口メタドンが休息している筋肉の交感神経活動 (MSA) を減少させるかどうかをテストする.
- ミュオオピオイド受容体阻害が麻酔下での解毒中にこの効果を逆転させるかどうかを判断する.
主な方法:
- メタドン療法を受けた15人のオピオイド中毒患者の経口MSAおよびカテキオラミンレベルを評価した.
- MSAとカテキオラミンを健康な対照群と比較した.
- プロポフォール麻酔中のナロキソン (ミュオピオイドアンタゴニスト) の評価された効果.
主要な成果:
- 休息時のMSAとノレピネフリン濃度は,メタドンで治療を受けた患者では,対照群と比較して有意に低かった.
- ナロキソンによるムオピオイド受容体阻害は,MSA,ノレピネフリン,エピネフリン,血圧,心拍数を著しく増加させた.
結論:
- メタドンによる慢性的なミュオピオイド受容体刺激は,ヒトの休息状態のMSAを減少させます.
- これは,メタドンが交感神経系の活動を調節することを示唆しています.
関連する概念動画
Cholinergic Receptors: Muscarinic
4.9K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.9K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.3K
Opioid Receptors: Overview
7.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.4K
Analgesia and Pain Management
3.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.4K


